Janssen Pharmaceuticals, Inc. Completes Divestiture of U.S. License Rights to NUCYNTAÂ® (tapentadol), NUCYNTAÂ® ER (tapentadol) extended-release tablets and NUCYNTAÂ® (tapentadol) Oral Solution to Depomed, Inc.